Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Renal Denervation Devices Market Size

The global renal denervation devices market size was valued at USD 92.68 million in 2025 and is projected to grow from USD 127.25 million in 2026 to USD 1607.02 million by 2034, registering a CAGR of 37.3% during the forecast period from 2026 to 2034. North America dominated the renal denervation devices market with a market share of 39.5% in 2025.

Renal denervation (RDN) has emerged as a groundbreaking approach for managing drug-resistant hypertension, a condition where conventional medications fail to adequately control high blood pressure. This innovative technique targets the renal sympathetic nerves, which play a critical role in blood pressure regulation. By disrupting these nerves, RDN helps to reduce the hyperactivity that contributes to elevated blood pressure.

Several RDN methods are currently in development, including the use of radiofrequency energy, ultrasound, and neurolytic agents. Each of these techniques focuses on diminishing nerve activity around the renal arteries, aiming to achieve a sustained reduction in blood pressure. Radiofrequency energy applies controlled heat to ablate the nerves, while ultrasound uses high-frequency sound waves for non-invasive nerve disruption. Neurolytic agents, on the other hand, involve chemical methods to achieve nerve modulation.

Together, these cutting-edge approaches offer promising alternatives for patients with hypertension that is unresponsive to traditional therapies, potentially revolutionizing the way resistant hypertension is treated.

Emerging Market Trends

Rising Clinical Research and Long-Term Benefits

The shift towards an increasing investment in clinical studies, research, and development related to these renal denervation devices, as well as the proven long-term benefits of renal denervation procedures, is a key market trend propelling the growth of renal denervation devices.

• For instance, in April 2022, an article published in Nature highlighted that over 80% of Thai patients with resistant hypertension achieved successful outcomes with renal nerve denervation, with these benefits being maintained over an extended follow-up period and without any intervention-related side effects.

Technology Insights

The global renal denervation devices market is bifurcated into radiofrequency-based, ultrasound-based, micro-infusion-based, and others. The radiofrequency-based segment dominates renal denervation devices due to its long-standing presence in the market and the significant number of successful procedures performed using this technology. This method involves using radiofrequency energy to disrupt overactive renal nerves and has been widely adopted since its introduction.

• For instance, in May 2024, Kauvery Hospital in India launched a new radiofrequency-based renal denervation therapy for chronic hypertension. Approved by the Indian government, this method showed positive results in reducing nerve activity and managing severe, medication-resistant high blood pressure, underscoring the technology's market dominance.

Request Customizationto receive a tailored report.

End-User Insights

The global market is divided into hospitals & clinics, ambulatory surgery centers, and others. The hospitals and clinics segment dominates the renal denervation devices industry due to their advanced infrastructure, specialized staff, and resources for complex procedures. These facilities are particularly effective in managing resistant hypertension cases, benefiting from established reimbursement frameworks and supportive healthcare policies that facilitate access to cutting-edge treatments.

In addition to their primary functions, hospitals and clinics play a crucial role in conducting clinical trials that evaluate the safety and efficacy of new renal denervation technologies. This research not only advances the field but also helps in the early adoption of innovative devices and techniques into routine care. By actively participating in trials, these institutions contribute to the development of evidence-based practices, enhancing treatment protocols for hypertensive patients.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America accounts for the dominant position in the renal denervation market, driven by the high number of FDA approval requests and significant advancements in technology. In 2023, the FDA authorized two renal denervation devices in the U.S., including the “Symplicity Spyral System and Ultrasound-based Paradise Device”. The region's dominance is further supported by the high prevalence of hypertension, changing lifestyles, and an aging population.

Moreover, major domestic companies, including Kona Medical Inc., Boston Scientific Corporation, ReCor Medical, Inc., Mercator MedSystems, Inc., and Ablative Solutions, Inc. are strengthening their positions through R&D, mergers, acquisitions, and new product launches and are at the forefront to eliminate the rising hypertension cases in the region.

U.s Market Trends

The U.S. leads the North American renal denervation devices market, driven by a rising incidence of uncontrolled hypertension. As healthcare providers increasingly recognize the importance of addressing resistant hypertension, innovative treatment options are gaining traction. For instance, in November 2023, Medtronic plc received FDA approval for its Symplicity Spyral renal denervation system.This system offers a new minimally invasive treatment approach, representing a significant advancement in the management of hypertension. The approval not only enhances patient access to effective therapies but also strengthens the competitive landscape for renal denervation devices in the region.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Renal Denervation Devices Market Trends

The European region is experiencing rapid growth in the global market due to robust regulatory support and advancements in technology. The European Medicines Agency (EMA) has approved several new renal denervation devices, enhancing their availability across European countries.

Moreover, technological innovations, such as advanced ablation systems and multi-electrode catheters, have improved procedural accuracy and patient outcomes. Notable clinical trials, including the SPYRAL HTN studies, have validated these technologies' efficacy.

Germany Market Trends

As per the study published in the Journal of Hypertension in May 2024, a significant gender gap in hypertension management among older Germans is witnessed. The study found that while the prevalence of hypertension is similar between older men (58.3%) and women (59.5%), treatment and awareness rates are high for both sexes (around 97.5% and 81%, respectively). This requires the urgent need for advanced treatment options, such as renal denervation devices, which are gaining increasing research.

Uk Market Trends

As per the National Health Service, in May 2023, in the UK, the prevalence of hypertension among adults aged 65 and over is 60%, indicating a significant increase with age. This rising prevalence, especially among older adults, is driving the increasing demand for effective hypertension management solutions, boosting the market growth.

Italy Market Trends

The country is facing a higher prevalence of self-reported hypertension among men compared to women, which is raising the demand for renal denervation devices. For instance, according to a 2021 survey published by the National Institute of Health, 73.6% of participants in Italy were aware of their blood pressure status, with 42.3% having been diagnosed with hypertension and 41.4% using antihypertensive medications.

Asia Pacific Renal Denervation Devices Market Trends

India Market Trends

In India, government efforts to advance chronic hypertension treatment are exemplified by the India Hypertension Control Initiative (IHCI). As of June 2022, the IHCI reported significant progress, expanding its reach to 100 districts and enrolling over 2.5 million patients.Despite the country facing high hypertension rates, the initiative achieved an impressive 47% control rate among registered patients. This success demonstrates the effectiveness of low-cost treatment strategies, reinforcing the importance of public health initiatives in managing chronic conditions.

China Market Trends

In China, local medtech companies are making notable strides in the development of renal denervation devices. In 2023, Symap Medical and Shanghai Golden Leaf Medtec published promising clinical trial outcomes for their respective technologies. These advancements underscore the commitment of Chinese manufacturers to innovate and improve treatment options for hypertension.As the healthcare system evolves and the demand for effective hypertension management rises, these companies are positioned to play a critical role in the regional market. Moreover, the Chinese government's support for medical technology innovation and research is expected to foster further growth in this sector.

South Korea Market Trends

South Korean companies are also advancing rapidly in renal denervation technology. Notably, in June 2024, DeepQure launched an Early Feasibility Study for its renal denervation device, HyperQure. This multicenter, single-arm, open-label trial has received FDA approval under an investigational device exemption (IDE). It aims to evaluate the safety and efficacy of HyperQure in treating resistant hypertension in 15 U.S. patients.This initiative not only reflects South Korea’s commitment to pioneering new medical technologies but also highlights the global collaboration in hypertension treatment development.

Company Market Share

Leading players in the renal denervation market are heavily investing in R&D to expand their product lines and enhance market growth. Key strategies include new product launches, strategic partnerships, mergers and acquisitions, and local production to reduce costs. Major market players like Boston Scientific, Medtronic, ReCor Medical, and others are actively pursuing these strategies to strengthen their global presence.

Recor Medical, Inc.: An Emerging Player in the Global Market

Recor Medical, headquartered in Palo Alto, California, operates as a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. The company is an emerging player in the renal denervation devices industry , focusing on the innovation in chronic care therapies, dedicated to transforming the management of chronic diseases. The company is at the forefront of medical technology, specializing in cutting-edge solutions for hypertension management.

Recent Developments at Recor Medical, Inc. Include:

• In April 2024, Recor Medical, Inc., along with its parent company, Otsuka Medical Devices Co., Ltd., announced the FDA approval of the paradise ultrasound renal denervation system. This innovative technology, now commercially available, was recently implemented at Al Qassimi Hospital in Sharjah, UAE, marking its introduction to the Middle Eastern market. The Paradise system employs advanced ultrasound technology to target and disrupt overactive renal nerves, providing a novel solution for managing resistant hypertension.

List of Key and Emerging Players in Renal Denervation Devices Market